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Performance validity tests (PVT) are widely used in attempts to quantify effort and/or detect negative response 
bias during neuropsychological testing. However, it can be challenging to interpret the meaning of poor PVT 
performance in a clinical context. Compensation-seeking populations predominate in the PVT literature. We 
aimed to establish base rates of PVT failure in clinical populations without known external motivation to 
underperform.  
Methods 
We searched MEDLINE, EMBASE, and PsycINFO for studies reporting PVT failure rates in adults with defined 
clinical diagnoses, excluding studies of active or veteran military personnel, forensic populations, or studies of 
participants known to be litigating or seeking disability benefits. Results were summarised by diagnostic group 
and implications discussed.  
Results 
Our review identified 69 studies, and 45 different PVTs or indices, in clinical populations with intellectual 
disability, degenerative brain disease, brain injury, psychiatric disorders, functional disorders, and epilepsy. 
Various pass/fail cut-off scores were described. PVT failure was common in all clinical groups described, with 
failure rates for some groups and tests exceeding 25%.  
Conclusions 
Performance validity test failure is common across a range of clinical conditions, even in the absence of obvious 
incentive to underperform. Failure rates are no higher in functional disorders than in other clinical conditions. 
As performance validity test failure indicates invalidity of other attempted neuropsychological tests, the finding 
of frequent and unexpected failure in a range of clinical conditions raises important questions about the degree 
of objectivity afforded to neuropsychological tests in clinical practice and research.  
  





Performance validity tests, also historically called effort tests, are used by clinical psychologists to try to detect 
inadequate effort and exaggerated or feigned impairment. Identifying invalid performance has critical 
implications for how the psychologist interprets the rest of the neuropsychological examination, and may also 
have clinical and medicolegal implications.  
As clinicians in neuropsychiatry and neurology we often read neuropsychology reports which include reference 
to effort and validity measures. However, it can be difficult to interpret the significance of PVT failure in our 
patients, where complex combinations of neuropathological, cognitive, and emotional factors, including 
negative prior experiences with other health professionals, can influence symptom experience and behaviour in 
the consultation.  
Moreover, the PVT literature is difficult to assimilate in a clinically meaningful way. This is in part due to the wide 
range of free-standing and embedded measures described in different studies, and in part due to the range of 
mixed clinical and litigating populations tested. In addition, descriptions of tests and cut-offs provided are often 
limited, in view of concerns about the possibilities of preparation or coaching in litigants undergoing 
neuropsychological assessment1.  
Previous reviews have discussed the application, meaning, and interpretation of validity tests results2–4, have 
reviewed specific tests, or described PVT performance in specific groups. While some describe the proportion 
of examinees involved in seeking compensation, it is difficult to extract from these data a clear picture of 
performance in individuals who are ill and/or impaired and are not seeking compensation. 
We identified a clinical need for a clear summary of the rates of PVT failure in distinct clinical groups: i.e. by 
diagnosis. In our view, better understanding of how people with different clinical diagnoses perform in PVTs is 
an important preliminary to further research to understand what single or multiple factors we might be 
measuring when one of our patients ‘fails’ one or more PVTs.   





Our primary aim was to summarise the available published data on performance validity test failure rates in 
clearly defined (by diagnosis) non-litigating, non-forensic, non-military, non-military-veteran, clinical 
populations. Secondly, we aimed to consider the implications of our findings in terms of the uses of performance 
validity tests (PVTs) in clinical practice.  
Method 
Search strategy and selection criteria 
We systematically searched the published peer-reviewed English language literature in MEDLINE, Embase, and 
PsycINFO databases from inception to July 5th 2019. The search, screening, and data extraction were done by 
one author (LM), and the review was conducted in line with PRISMA guidelines5. The search terms used were 
[“performance validity test*” OR “symptom validity test*” OR “effort test*”]. We included studies reporting the 
results of performance validity tests (not symptom validity questionnaires) in one or more individuals with a 
recorded clinical diagnosis of a specific medical disorder. We excluded studies of mixed clinical populations, in 
which performance by diagnosis was not reported. We also excluded studies of children and adolescents (<16), 
forensic populations, studies in which ≥ 50% of participants were known to be involved in litigation or seeking 
welfare benefits, studies of active military personnel or military veterans, and studies involving assessments of 
individuals with possible Attention Deficit Hyperactivity Disorder (ADHD) or Post-traumatic Stress Disorder 
(PTSD). The reason for exclusion of these groups was that they are substantially more likely to be undergoing 
assessment where there is a potential incentive for financial compensation or other social advantages. However, 
it should be noted that it is also likely that the included studies included individuals with incentives to 
underperform which were unknown to the investigators. Studies describing attempts to assess the validity of 
self-reported symptoms were excluded, as they were considered outside the scope of the paper.  
Following the initial search and collation of data, additional title and keyword searches were performed on 15th 
January 2020, for the eight most frequently identified PVTs in the studies identified in the initial search. This 
search yielded an additional 11 eligible studies.  




Data were extracted independently by author LM using Excel, and synthesised into tables of test failure rate by 
diagnosis, with the aim of examining pooled failure rates for specific disorders in the context of a narrative 
review.  
 
Search results and screening 
[Figure 1 – Selection of included studies] 
45 different PVTs or indices were identified (supplementary table 1), and within these indices a range of cut-off 
scores were reported for many tests. The majority of results identified were for free-standing validity tests.  
Many of the validity tests identified (including the three most frequently reported tests: the Word Memory Test 
(WMT), Test of Memory Malingering (TOMM), and Medical Symptom Validity Test (MSVT)) used a forced choice 
paradigm. In a forced choice PVT, the examinee is asked to recognise previously seen words, pictures or numbers 
mixed with unseen foils in a 1:1 ratio. If the examinee correctly recognises significantly fewer than half (<18/50 
in the TOMM, on the basis of 90% confidence intervals), as would be expected if they were selecting answers at 
random, they are assumed to be preferentially selecting incorrect answers (intentionally or unintentionally). Of 
note, however, the cut-off scores for these tests were consistently much higher than the chance level, and the 
proportion of individuals scoring below the chance level was infrequently reported. The relevance of the use of 
a forced-choice paradigm was therefore unclear.  
Other tests used the ‘floor effect’: a cut-off score which it seems improbable that any individual applying full 
effort will score below. Reliable Digit Span (the fourth most commonly reported test, consisting summed 
maximum forward and backward digit span) and the Rey 15-item test, are examples of ‘floor effect’ validity tests. 
A small number of tests used an ‘atypical pattern’ principle. For example, in the dot counting test, examinees 
are expected to count grouped collections of dots more quickly than ungrouped dots and the absence of such a 
discrepancy (or reversed discrepancy) is taken as an indicator of invalid performance.  
Twenty-seven studies stated either that no litigating or compensation-seeking examinees were included. In 40 
studies, presence of litigation was not reported, but the population was recruited from a clinical or clinical 
research (rather than medicolegal) setting. In one study participants were informed that test results would not 




be made available and so could not be used to support compensation claims. Finally, one study examined adults 
seeking to regain custody of their children, who were presumably motivated to perform well6.  
Quality of included studies 
The potential for selection bias in included studies was significant. Many studies were conducted retrospectively 
on previously collected data. The methods for ascertaining clinical diagnoses were not always clearly described. 
Importantly, it should be assumed (in the absence of any evidence otherwise) that those examiners undertaking 
the validity tests were not blinded to clinical history and/or diagnosis of the examinees. Variable cut-off scores 
were used, as can be seen in the detailed discussion of results below and in the supplementary tables. Finally, 
despite our efforts to minimise possible influence of external incentives, the presence of undetected external 
(or internal) incentive cannot be excluded. 
Intellectual disability (supplementary table 2) 
Three studies described PVT performance in adults with intellectual disability. In Goldberg and Miller, 6/16 (38%) 
adults with mean IQ 63.9 failed (<9) the Rey 15-item test7. In the largest study included, 6 of 276 (2%) adults 
with intellectual deficits but full-scale IQ >70 seeking to regain custody of their children (and therefore expected 
to be motivated to pass) failed the Medical Symptom Validity Test (criterion A) and 11 of 223 (5%) failed the 
Word Memory Test6. In the same study, 14% (2) of 14 individuals in the same circumstances but with FSIQ ≤70 
failed the Word Memory Test and 0 of 17 failed the Medical Symptom Validity Test6. 
Mild cognitive impairment (MCI) (supplementary table 3) 
Nine studies reported PVT performance in mild cognitive impairment (MCI) or minor neurocognitive disorder, 
constructs in which measurable cognitive impairment is present which is not severe enough to merit diagnosis 
of dementia and which is not associated with functional impairment. The highest reported failure rates were 
42% (153 of 365) individuals with amnestic MCI in Loring et al.; 36% (29) of 80 with minor neurocognitive 
disorder failed the Rey 15-item test (cut-off <20) in Fazio et al.; 27% (1462) of 5414 with MCI failed the logical 
memory test (cut-off <14) and 25% (1354) of 5414 failed semantic word generation (cut-off <13) in Daviset al, 
and 22% (13) of 60 individuals with ‘probable MCI’ in Green et al.8–11.  Of note, 11 of the 13 MCI individuals in 
Green et al. 2011 who failed criterion A of the Word Memory Test did not meet criterion B (easy – hard difference 




<30) and so had a possible dementia profile11. Pooled failure rates for Reliable Digit Span in MCI were 16% (83 
of 533) at a cut-off of ≤78,12, and 1% (6/613) at a cut-off of ≤58,9,12. 
Functional disorders (supplementary table 4) 
Eleven studies described PVT performance in people with functional disorders, including for the purposes of this 
review those conditions termed ‘medically unexplained’, somatoform or ‘nonorganic’. Where possible, PVT 
failure rates were pooled by specific condition. In two studies of individuals with fibromyalgia, 8% (8) of 104 
failed the TOMM13,14. In three studies of psychogenic non-epileptic seizures (PNES, also called dissociative 
seizures), 10% (13) of 132 failed the TOMM15–17. In two other studies of PNES, 44% (25) of 57 met criterion A 
(therefore failed) on the standard Word Memory Test18,19. In two studies of individuals with chronic fatigue 
syndrome, 25% (374) of 1526 failed the Amsterdam Short Term Memory Test (scoring <86/100)20,21.  
Failure rates higher than 25% were reported by Tyson et al in 33 individuals with psychogenic non-epileptic 
seizures on Reliable Digit Span (cut-off ≤7), vocabulary – digit span (≥3), forced choice recall on the CVLT (≤15), 
and the Boston Naming Test17.  
Epilepsy (supplementary table 5) 
Eleven studies reported PVT performance in people with epilepsy. In five studies including 246 people with 
epilepsy, 13% (31) failed the TOMM15–17,22,23. In three studies including a total of 74 people with epilepsy, 19% 
met criterion A of the standard version of the Word Memory Test19,24,25.  Two studies reported Reliable Digit 
Span results in people with epilepsy. Maiman et al. reported a failure rate of 23% (14/63) at a ≤7 cut-off and 10% 
(6/63) at a ≤5 cut-off, and Tyson et al. reported a failure rate of 45% (32/72)  at a ≤7  cut-off; the two studies 
producing a pooled RDS failure rate in epilepsy of 34% at a ≤7 cut-off.  
Notably, Tyson et al. reported higher failure rates in epilepsy compared with a group with Psychogenic Non-
Epileptic Seizures (see supplementary table 4) in six of eight tests included (TOMM, RDS, digit span, Boston 
naming test, complex ideational material, logical memory recognition trial) with failure rates higher in PNES than 
epilepsy only in vocabulary – digit span, and the forced choice test of CVLT. Of the two other studies comparing 
these groups, Cragar et al. reported higher failure rates in PNES than epilepsy (14% vs 2% on TOMM), as did 




Drane et al. (48% vs 8%), but Hoskins reported similar failure rates on the standard Word Memory Test in 
epilepsy and PNES (31% and 29% respectively). 
Acquired brain injury (supplementary table 6) 
The studies included in supplementary table 6 describe PVT performance in clinical groups falling under a broad 
acquired brain injury definition: irreversible but non-progressive structural brain injury, including traumatic and 
hypoxic brain injury, stroke, and Korsakoff’s syndrome.  
Eight studies described PVT performance after mild Traumatic Brain Injury (TBI). Results in this group as a whole 
were highly variable, suggesting between-group differences. Most studies in mild TBI reported low PVT failure 
rates (<20%). In contrast, however, Novitski et al. reported failure rate of 52% (13/25) on RBANS digit span (cut-
off <9) in 25 individuals who had sustained a mild TBI more than six months previously, and Erdodi et al. 2017 
reported failure using a liberal cut-off on the TOMM in 53% of 20 adults after mTBI 22,26. Similarly, Sherer et al. 
reported 25% of 118 people with mild TBI failed on criterion A of the Word Memory Test: the same failure rate 
(25%, or 38/150) as that reported in the severe TBI population described in the same study27. 
Grouping together moderate and severe brain injuries in what we consider a clinically relevant way 
(communication impairments prevent testing in those with the most severe injuries), three studies reported 
Word Memory Test results after moderate and severe brain injury, resulting in a pooled failure rate of 28% (63 
of 228; 95% CI 22-34%)25,27,28. Results of other tests studied in moderate and severe brain injury were 
heterogeneous. Macciochi et al. in 2006 reported 0% failures on the Victoria Symptom Validity Test in 71 adults 
a mean 43.4 days after severe brain injury29. The same group in 2017 reported poor performance on the delayed 
recall (failure in 5/9), and consistency (4/9) components of the Medical Symptom Validity Test during the post-
traumatic amnesia phase after brain injury but lower failure rates after resolution of post-traumatic Amnesia30. 
Erdodi et al. reported high failure rates on validity indices derived from the WAIS31. 
A study reporting validity test performance after stroke with initial aphasia found low failure rates on the 
(standard, pictorial) TOMM measures (7% (1/15 failing trial 2 and 0 failing the retention trial, but high failure 
rates on the Rey 15-item, RDS (<7) and reliable spatial span (60%, 73% and 40% respectively)32.  




One study described a single case of surgical removal of medial temporal lobe structures, and another described 
three cases of bilateral hippocampal atrophy after anoxic brain injury; none of these four individuals failed the 
Word Memory Test33,34. Oudman et al. reported that 2 of 20 individuals (10%) with Korsakoff Amnesia failed the 
2nd trial of the TOMM35. 
Neurodegenerative disease (supplementary table 7) 
Neurodegenerative disorders featured in 20 included studies – a greater number than any other group of 
conditions. The wide range of disorders, severities, tests, and test cut-off scores prevented calculation of 
meaningful pooled failure rates, although in general, failure rates were high (supplementary table 7, figure 2).  
The Word Memory and Medical Symptom Validity Tests were most frequently described. Green et al. reported 
high failure rates in clinically defined ‘probable, mild, and moderate’ dementia on the Word Memory Test (71% 
of 42) and Medical Symptom Validity Test (48% of 23), but reported that all who failed met the ‘dementia or 
severe impairment profile’, a profile of results defined by the test author as typical of dementia or severe 
impairment rather than non-credible performance11. Howe et al. reported failure rates of 38% on the Medical 
Symptom Validity Test in 13 with mild dementia, all of whom met the ‘dementia profile’, and 83% (of 18)  in 
advanced dementia of whom 15 met the ‘dementia profile’36. 18 of 20 (90%) mild Alzheimer’s dementia 
examinees in Merten et al’s study failed the delayed recall component of the Word Memory Test, even though 
a cut-off (34%) significantly lower than the standard cut-off(45%) was applied37. Rudman et al. and Singhal et al. 
both reported high failure rates (73% of 22, and 100% of 10) in advanced dementia on the Medical Symptom 
Validity Test38,39.  
Two studies reported validity test results in individuals with Parkinson’s disease undergoing testing in the 
workup for possible deep brain stimulation40,41. Here, failure rates were reasonably low – at most 5 of 47 (10%) 
failed the Medical Symptom Validity Test in Wodushek et al  - but this 10% might also be considered a rather 
higher failure rate than expected in individuals without gross cognitive impairment in whom there is an incentive 
(in the form of access to a potentially beneficial treatment) to perform well on neuropsychological testing40.  




Psychiatric disorders (supplementary table 8) 
Studies of schizophrenia, schizoaffective disorder, and other psychotic disorders generally reported relatively 
high failure rates on a range of validity tests. The highest failure rate reported was in 72% of 64 individuals with 
schizophrenia on the Word Memory Test42. In contrast, Schroeder et al’s study of 104 individuals with a 
‘psychotic psychiatric disorder’ reported low failure rates on a range of embedded tests, including 4% failure on 
RDS with a <=6 cut-off and 3% failure on finger-tapping43. Whearty et al’s 2015 study of 60 individuals with 
schizophrenia or schizoaffective disorder reported that 28% failed Reliable Digit Span ≤6 and 36% failed finger-
tapping44.  
Two studies examined performance validity in depression, Lee et al. reporting low failure rates(<=5%) on the 
Rey 15-item and dot counting tests and Rees et al. reporting no failures on the TOMM in 26 inpatients with 
depression45,46.  
Dandachi-Fitzgerald compared Amsterdam Short-Term Memory test performance in different psychiatric 
diagnoses: failure rates were 31% of 16 with personality disorders, 25% of 8 with psychotic disorders, 18% with 
substance abuse/dependence, 16% with ASD and 14% with ADHD47. Price et al. reported no failures on the 
TOMM in 71 individuals with methamphetamine dependence48. 
Other conditions (supplementary table 9) 
Heintz et al. reported 23% of 13 individuals with Gilles de la Tourette syndrome failed the ASTM49. Two studies 
reported validity results in people with HIV – in one study 15% of 111 people with HIV (stable on antiretroviral 
therapy) failed trial 1 of the TOMM (note, TOMM is usually scored on trial 2 or a delayed trial); and in another 
17% of 30 failed the Amsterdam Short-Term Memory test 50,51. A study of neuropsychological performance in 
adults with sickle cell disease reported low failure rates on the TOMM and on RDS <=6, but 33% of 43 failed 
Reliable Digit Span with a <=7 cut-off52. In Rossetti et al. 2 of 10 deep brain stimulation candidates with essential 
tremor failed the Word Memory Test41. 
Comparative analysis of PVT results between groups 
The heterogeneity of populations, tests, and in some cases cut-off scores used, makes comparisons difficult.   




Failure rates (with confidence intervals), by study, in the most frequently reported validity tests are displayed 
graphically, by diagnostic heading, in Figure 2. Error margins are wide due to the small numbers in most studies. 
Allowing for this, however, it is clear that PVT failure is common in a range of clinical groups. 
[Figure 2 - failure rates in the 12 most frequently reported tests by diagnosis. Each point represents reported 
failure rate, in a particular test (indicated by colour), as reported by an individual study. Points are grouped along 
the x axis in the same test (colour) order in each plot, so as to allow visual comparison between plots. Vertical 
lines indicate the asymptotic 95% confidence interval for each reported failure rate.] 
Discussion 
Our review suggests that failure of performance validity tests during neuropsychological assessment is not a rare 
phenomenon, but is common in many clinical groups. Of note, validity test failure is particularly likely in 
moderate and severe traumatic brain injury, and both mild and moderate-severe dementia (where the ‘severe 
impairment’ profile on the Word Memory Test often applies). Of note, whilst some individuals with functional 
disorders fail PVTs, failure rates are no higher than in a range of other diverse conditions, including epilepsy, and 
mild cognitive impairment.  
Remarkably few studies in the very large validity test literature describe performance by clinical diagnosis. Even 
some studies which appear to do so often group together different illness or injury severities in a way that 
renders the data difficult to apply to clinical practice. For example, studies of validity tests in traumatic brain 
injury populations mixed those with mild, moderate and severe injuries, in whom vastly different cognitive and 
symptom profiles would be expected. These studies were excluded from our review on this basis, but it is likely 
that there is still a degree of heterogeneity in the included studies.    
We aimed to select studies of individuals without clear external incentives to fail. It is of course possible that 
these factors were present in some cases, unknown to the investigators. Indeed, we would argue that a range 
of external motivators and internal factors influence how people behave during the majority of conscious 
encounters in most areas of healthcare. One possibility to explain our results, therefore, is that many patients 
do not apply the degree of effort that we would like them to apply, intentionally or unintentionally, for reasons 
that we cannot always immediately perceive or understand. 




It seems much more likely, however, that PVTs, using commonly-applied cut-offs, are in fact not only measuring 
deficient effort but a whole range of factors, including memory impairment, apathy, fatigue, or attention deficit 
due to pain or other cognitive or somatic symptoms. People who have symptoms of any sort, in any condition, 
are liable to divert attention towards those symptoms. If attention is conceptualised as a finite resource (more 
accurately, attentional processes govern use of finite processing capacity), we suggest it is possible to fail almost 
any ‘floor-level’ test if there is not enough spare attention available to allocate to the task.  
Many of the tests reported by included studies are based on a ‘forced choice’ paradigm. Scoring comfortably 
below the level of chance in a forced choice validity test has been used as evidence of deliberate exaggeration 
of impairment – intention to fail – which most would acknowledge is qualitatively different from, rather than on 
a spectrum with, not applying sufficient effort. In our experience there is a widely-held view that less-than-
chance performance is precisely what PVTs are used to detect. However, our review demonstrates is that this is 
not really the case. Without exception, the cut-off scores used in PVTs are much higher than chance (defined as 
50% or ideally lower, to allow for error): most test cut-offs are between 80% and 90%. We suggest that using a 
forced choice paradigm with cut-off scores greatly exceeding chance makes the forced choice element 
redundant, and that the test instead functions as a ‘floor level’ test, vulnerable to functional attentional deficit 
in people with symptoms of any sort. We feel it is important to point out that failure at accepted cut-off levels 
on commonly-used forced choice tests – the TOMM, the Word Memory Test, and the Medical Symptom Validity 
Test – does not demonstrate intention to fail.  
Inadequate attentional focus on a PVT might sometimes result from diversion of attention in adaptation to 
symptoms and associated disability. In other situations, however, excessive focus on the task may be an intrinsic 
feature of the disorder being tested. In functional neurological disorders, clinical experience and experimental 
evidence show that excessive or misdirected effort interfere with normal performance. For example, patients 
with functional motor disorders who are unable to walk may be able to walk backwards, or to run – essentially 
when engaged in tasks which divert attention away from deliberate and effortful processes so that automatic 
movement-control processes to take over. Similarly, people with functional cognitive disorders can struggle and 
underperform when trying hard on cognitive tests but demonstrate intact cognition by providing effortless and 
detailed descriptions of memory lapses53,54. We wonder if individuals with functional neurological disorders 
might in some cases paradoxically fail PVTs because of an excessive degree of effort, where the harder they try, 




the worse their performance. Hoover's sign of functional leg weakness depends on demonstrating impaired 
'effort' in hip extension which returns to normal with contralateral hip flexion. Our clinical experience with 
patients with functional leg weakness is that the more they try the weaker their movements are. 
Our experience of screening studies for this review illustrates some of the problems and difficulties that have 
arisen in validating performance validity tests.  
The poor quality of the PTV evidence base examined here, with a lack of blinding to diagnosis and potential for 
selection bias, is in itself a key finding of the review.  
The majority of excluded studies reported validity test from mixed groups of people with a wide range of 
different conditions attending for neuropsychological assessment, and did not report test results by diagnosis. 
The reason for this clumping is of course that the question investigators have been interested in is not ‘How do 
people with different clinical conditions perform in PVTs?’ but ‘How can I identify a non-credible performance 
regardless of clinical condition?’ Mixed groups are either compared with simulators, or split into ‘credible’ and 
‘noncredible’ groups for the purposes of a known-groups design.  Slick, Sherman and Iverson’s criteria for 
‘probable malingered neurocognitive dysfunction’, or similar definitions, are frequently used to define 
‘noncredible’: a) motive to feign symptoms (litigation or seeking disability compensation), b) failure on two 
independent performance validity tests, and c) evidence of inconsistency between self-reported symptoms and 
observed behaviour55.  
Examination of these criteria quickly makes apparent some of the difficulties in establishing a ‘gold standard’ for 
invalid performance. Firstly, the presence of an external incentive, particularly in the form of seeking disability 
benefit, while it may increase the chance of invalid performance, also selects out a group of people who are ‘ill’ 
and have a range of other reasons to perform poorly. While this review did not include studies of primarily 
litigating or disability-benefit seeking populations in order to minimise the influence of major external influences 
on performance, we suggest that there are many reasons for people with ‘external incentives’ to fail PVTs other 
than inadequate effort or intention to fail.  
The second ‘malingered neurocognitive dysfunction’ criterion55, failure on two independent PVTs, relies on an 
assumption that those tests are indeed measuring something akin to effort. Alternatively, we suggest that failure 
on multiple PVTs indicates that ‘something’ is going on, but does not tell us that that ‘something’ is inadequate 




effort or wilful exaggeration. The assumption that PVTs primarily measure effort is pervasive in the PVT literature 
and is reinforced by reporting of sensitivity and specificity metrics, with use of the term ‘false positive’ to 
describe failure in a ‘credible’ participant.  
Finally, inconsistency between cognitive scores and level of function in activities of daily living is in our 
experience common in functional neurological disorders, and also in certain psychiatric disorders.  
An important question is, therefore, why is it so difficult to find a ‘gold standard’ here? We suggest firstly that 
inadequate effort – ‘not trying hard enough’ – is highly subjective, is not a binary variable with a single 
dimension, and depends on a mixture of cognitive and emotional processes. Importantly, we consider that 
‘inadequate effort’ is qualitatively different from deliberate exaggeration or intentional failure (as defined by 
Slick et al.55). And yet, by using these criteria to divide examinees into credible and non-credible groups, 
researchers use a definition for the latter (malingered dysfunction) to establish cut-offs for the former 
(inadequate effort).  
Importantly, the manner in which we have described PVT failure rates does not necessarily reflect how they are 
used in practice by skilled clinical neuropsychologists, although where there is certainly expertise there is little 
consensus56. Published guidance documents for neuropsychologists are clear to point out limitations, including 
various reasons for test failure, and limited evidence in clinical populations57,58.  Guidance documents 
recommend that multiple performance validity measures should be used, including both free-standing and 
embedded indicators, and emphasise that PVTs should be interpreted as part of the wider context of the 
assessment.  
Finally, it is important to remember that the key purpose of validity tests should be not to assess the validity of 
the person being tested, but the validity of the results of other neuropsychological tests. While what we are 
measuring in PVTs remains unclear, what is much clearer is that poor performance on PVTs renders other 
neuropsychological tests invalid59. One analogy is of movement artefact on an MRI scan; there are many reasons 
that a person might move during an MRI scan, but a single common end result: degradation of the images so 
that they are difficult or impossible to interpret.  While PVT failure tells us that there is a problem with the image 
drawn by the other neuropsychological tests, it is not always possible to fully understand the reasons for that 




interference.  We suggest that future research in clinical groups with a range of symptom and impairment 
complexes is one possible route to better understanding of the factors influencing performance.  
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Table 1 - PVTs / performance validity tests in included studies 
Test name (acronym) Free-standing / embedded Type of test N studies 
reporting 
test 
Word memory test (WMT)  Free-standing Forced choice 18 
Test of memory malingering (TOMM) Free-standing Forced choice 16 
Medical Symptom Validity Test (MSVT) Free-standing Forced choice 11 
Reliable Digit Span (RDS)  Free-standing  
or embedded (in WAIS) 
Floor effect 10 
Amsterdam Short Term Memory Test (ASTM) Free-standing Forced choice 5 
Victoria Symptom Validity Test (VSVT) Free-standing Forced choice 5 
Rey 15-item Test Free-standing Floor effect 4 
RBANS Effort Index Embedded  Floor effect 4 
Coin-in-the-hand Test Free-standing Forced choice 3 
Dot counting Free-standing Atypical pattern 3 
Finger tapping Free-standing Floor effect 3 
Vocabulary - digit span Embedded (WAIS) Atypical pattern 3 
California Verbal Learning Test II forced choice Embedded (CVLT) Forced choice 2 
Digit Symbol Coding Embedded (WAIS) Floor effect 2  
Rey Word Recognition Test Free-standing Forced choice OR Atypical 
pattern (with RAVLT recall) 
2 
Visual Association Test-Extended Free-standing Forced choice 2 
Logical Memory  Embedded(WMS) Floor effect 2 
Mental Control test Embedded (WAIS) Floor effect 2 
Autobiographical Memory Inventory Free-standing Floor effect 2 
Digit span Embedded (WAIS) Floor effect 2 
Rey-Osterrieth Complex Figure Test equation: 
copy score + [(true positive recognition – 
atypical recognition errors) x 3 
Embedded (ROCFT) Atypical pattern + floor effect 2 
Hiscock Digit Memory Test / Hiscock forced 
choice test 
Free-standing Forced choice 2 
Validity Indicator Profile (VIP) verbal, Symbol Search, Portland Digit Recognition Test, b-Test, Rarely missed 
index, Sentence repetition, Rey Auditory Verbal Learning Test equation, Camden memory test for faces, Camden 
Pictorial Recognition Memory Test, Wechsler Adult Intelligence Scale (WAIS) processing speed index, Digit 
Memory Test (DMT), Semantic word generation raw score, Repeatable Battery for the Assessment of 
Neuropsychological Status (RBANS) Effort Scale, Short Test of Mental Status (STMS), Rey Complex Figure Test 
(RCFT), Letter Memory Test (LMT), Trail Making Test B:A ratio, reading subtest of Wide Range Achievement Test, 
fourth edition (WRAT-4), elements of the Auditory Verbal Learning Test (AVLT), Reliable spatial span, Coding 
age-corrected scaled score, Wechsler Adult Intelligence Scale (WAIS) effort index, Warrington Words 
1 each 




Tables (2-9) summarising reported failure rates (percentages) by diagnosis 
(percentages highlighted in red indicate > 25% failure rate) 
 
Table 2 - Intellectual disability (percentages ≥25% highlighted in red) 
Intellectual disability 
Study* Clinical definition Test (cut-off) N % to fail 
test 
Goldberg and Miller 
1986 
“intellectually deficient individuals”: IQ 40-69 (mean 63.9) Rey 15-item test (< 
9) 
16 38% 




Green and Flaro 
2015 
 
adults with intellectual deficits (full-scale IQ (FSIQ) ≤70) seeking to regain 
custody of their children 
 
WMT (criterion A) 14 14% 




adults with intellectual deficits (FSIQ >70) seeking to regain custody of their 
children 
 
WMT (criterion A) 223 5% 
MSVT (criterion A) 276 2% 
* References for all included studies are available in the supplementary file ‘List of included studies’ 
 
  




Table 3 - Mild cognitive impairment (MCI)  (percentages ≥25% highlighted in red 
Mild cognitive impairment (MCI) 
Study Clinical definition Test (cut-off) N % to fail test 
Howe et al. 2007 MCI MSVT (criterion A) 16 13% 
Duff et al. 2011 amnestic MCI RBANS Effort Index (>3) 72 0% 
Green et al. 2011 possible MCI WMT (criterion A) 60 22%* 
Walter et al. 2014 MCI TOMM trial 2 (≤45) 31 10% 




RDS (≤5) 365 1% 
RDS (≤7) 14% 
AVLT recognition (≤9/15) 42% 




RDS (≤5) 168 
 
1% 
RDS (≤6) 5% 
RDS (≤7) 19% 




VAT-E (Visual Association Test-Extended) IR  (≤21) 76 0% 
VAT-E DR  (≤20) 1% 
VAT-E CNS  (≤21) 4% 





Digit Symbol Coding AASS (<6) 5414 
 
3% 
Digit Span AASS (<6) 4% 
Logical memory (<14) 27% 
Semantic word generation (<13) 25% 
Trail Making Test B:A ratio (<1.5) 3% 
Fazio et al. 2019 
 
Minor neurocognitive disorder Rey 15-Item Test (recall <20) 80 
 
36% 
RDS (≤5) 0% 
*11/13 ‘possible dementia profile’ – profile of results suggestive of failure due to dementia rather than invalid performance 




Table 4 - Functional and somatoform disorders (percentages ≥25% highlighted in red) 
Functional and somatoform disorders 









al. 2006  
  
Psychogenic non-epileptic seizures () 
 
LMT (<93%) 21 
 
23% 
DMT (<90%) 5% 
PDRT-27 (<54%) 14% 
TOMM trial 2 (≤45) 14% 
TOMM retention (≤45) 14% 
both epilepsy and psychogenic non-epileptic seizures 
(PNES) 
 
LMT (<93%) 18 
 
5% 
DMT (<90%) 5% 
PDRT-27 (<54%) 0% 
TOMM trial 2 (≤45) 0% 
TOMM retention (≤45) 5% 
Drane et 
al. 2006 
Psychogenic non-epileptic seizures  WMT (criterion A) 43 48% 
Heintz et 
al. 2013 
Psychogenic movement disorder with jerk-like 
movements 
ASTM (≤85) 26 24% 
Hill et al. 
2003 






Psychogenic non-epileptic seizures WMT oral (criterion A) 16 44% 






TOMM trial 1 (not stated) 54 0% 
TOMM trial 2 (not stated) 0% 
TOMM retention (not stated) 0% 
Kemp et al. 
2008 
  
patients with medically unexplained symptoms  
(20 psychogenic non-epileptic seizures, 14 functional 
movement disorder/paralysis, 4 nonorganic sensory 
deficit, 2 functional blindness, 1 fibromyalgia, 1 
nonorganic neuropsychological complaints) 
MSVT IR (≤85) 43 
 
12% 
MSVT DR (≤85) 12% 
Coin-in-hand test (≤7/10) 9% 
Autobiographical Memory Index 
(≤9) 
5% 
Camden Pictorial Recognition 
Memory Test (<5th age-related 
centile using upper limit sample) 
19% 
Mental Control Test (<5th age-




Werf et al. 
2000 
Chronic fatigue syndrome ASTM (<86) 144 29% 
Roor et al. 
2018 
Chronic fatigue syndrome ASTM (≤85) 1382 24% 
Tyson et al. 
2018 
Psychogenic non-epileptic seizures TOMM (trial 1 ≤39 or trial 2 ≤44) 33 13% 
RDS (≤7) 27% 
Digit span age-corrected scaled 
score (≤6) 
22% 
vocabulary – digit span (≥3) 26% 
Forced choice recall test of CVLT 
(≤15) 
32% 




FAS and animals verbal fluency 
(≤33) 
24% 
Boston Naming Test (≤37) 25% 
Complex Ideational Material 
(≤29) 
10% 
Logical Memory Recognition 
trial (≤20) 
13% 




Table 5 – Epilepsy (percentages ≥25% highlighted in red) 
Epilepsy 
Study Clinical definition Test (cut-off) N % to fail test 
Cragar et al. 
2006 
  
epilepsy LMT (<93%) 41 17% 
DMT (<90%) 5% 
PDRT-27 (<54%) 2% 
TOMM trial 2 (≤45) 2% 
TOMM retention (≤45) 2% 
both epilepsy and psychogenic non-
epileptic seizures 
LMT (<93%) 18 5% 
 DMT (<90%) 5% 
PDRT-27 (<54%) 0% 
TOMM trial 2 (≤45) 0% 
TOMM retention (≤45) 5% 
Drane et al. 
2006 
epilepsy WMT criterion A 41 8% 
Grote et al. 
2000 
epilepsy VSVT(<16/24 difficult correct) 30 7% 
Erdodi et al. 
2017 (2) 
epilepsy TOMM trial 2 (≤48) 22 9% 
Hampson et al. 
2014 
  
epilepsy WMT-IR 16 6% 
WMT-DR 13% 
WMT-CR 38% 
WMT criterion A 38% 




digit-symbol coding (not 
stated) 
25% 
Camden memory test for faces 
(ns) 
6% 
Mental Control Test (ns) 15 27% 
Hill et al. 2003 epilepsy (temporal lobe)  TOMM (≤45) 48 4% 
Hoskins et al. 
2010 
epilepsy WMT oral (criterion A) 14 14% 
WMT (criterion A) 17 31% 
Keary et al. 
2013 
medically intractable focal epilepsy VSVT (<18/24 hard items) 404 5% 
Loring et al. 
2005 
epilepsy VSVT (<18/24 hard items) 120 12% 
Tyson et al. 
2018 
epilepsy TOMM (<45) 72 35% 
RDS (≤7) 45% 
Digit span age-corrected scaled 
score (≤6) 
45% 
vocabulary – digit span (≥3) 21% 
Forced choice recall test of 
CVLT (≤15) 
12% 
FAS and animals verbal fluency 
(≤33) 
51% 
Boston Naming Test (≤37) 68% 




Complex Ideational Material 
(≤29) 
31% 
Logical Memory Recognition 
trial (≤20) 
18% 
Maiman et al. 
2019 
epilepsy or suspected seizures RDS (≤6) 63 15% 
RDS (≤7) 23% 
RDS (≤5) 10% 
TOMM trial 1 (≤45) 35% 








Table 6 - Acquired brain injury (percentages ≥25% highlighted in red) 
Acquired brain injury 
Study Clinical definition Test (cut-off) N % to 
fail 
test 
Rees et al. 1998 mild traumatic brain injury TOMM (<45 trial 2) 10 0% 
Allen et al. 2011 mild traumatic brain injury WMT (criterion A) 1 0% 
Erdodi et al. 2017 mild traumatic brain injury WAIS processing speed index (≤68) 52 0% 
Coding age-corrected scaled score 
(≤4) 
6% 
Symbol Search age-corrected scaled 
score (≤4) 
2% 
WAIS EI 5 (Digit span, CVLT-II, WMS-
IV Logical memory, letter and animal 
fluency) (≥5) 
18% 
WAIS EI 5 (FCR) (≥4) 13% 
WAIS EI 5 (PSP) (≥4) 18% 
moderate-severe traumatic brain injury WAIS processing speed index (≤68) 10 30% 
Coding age-corrected scaled score 
(≤4) 
30% 
Symbol Search age-corrected scaled 
score (≤4) 
20% 
WAIS EI 5 (Digit span, CVLT-II, WMS-
IV Logical memory, letter and animal 
fluency) (≥2) 
44% 
WAIS EI 5 (FCR) (≥4) 40% 
WAIS EI 5 (PSP) (≥4) 25% 
Erdodi et al. 2017 
(2) 
mild traumatic brain injury TOMM (≤48 trial 2 or retention) 20 53% 
Hoskins et al. 2010 mild head trauma WMT oral (criterion A) 10 50% 
WMT (criterion A) 11 27% 
Macciocchi et al. 
2006 
acute severe traumatic brain injury (mean 
43.4 days post injury) 
VSVT combined scores (<30 invalid) 71 0% 
Macciocchi et al. 
2017 
moderate-severe traumatic brain injuryin 
post-traumatic amnesia (orientation log 
20-24) 
MSVT IR (≤85) 9 11% 
MSVT DR (≤85) 55% 
MSVT CNS (≤85) 44% 
moderate-severe traumatic brain 
injurynot in post-traumatic amnesia 
(orientation log 25-29) 
MSVT IR (≤85) 51 6% 
MSVT DR (≤85) 10% 
MSVT CNS (≤85) 26% 
moderate-severe traumatic brain 
injuryunimpaired on orientation log 
(30/30) 
MSVT IR (≤85) 17 0% 
MSVT DR (≤85) 0% 
MSVT CNS (≤85) 12% 
Novitski et al. 
2012 
mild traumatic brain injury, > 6/12 post 
injury 
RBANS digit span (<9) 25 52% 
Sherer et al. 2015 mild traumatic brain injury (GCS 13-15) WMT (criterion A) 118 25% 
moderate traumatic brain injury (9-12) WMT (criterion A) 47 28% 
severe traumatic brain injury (GCS 3-8) WMT (criterion A) 150 25% 
Wu et al. 2010 severe traumatic brain injury (GCS 3-8) WMT (criterion A) 2 0% 
 




Hampson et al. 
2014 
brain injury (acute moderate-severe 
(post-traumatic amnesia >24h, GCS 
<12/15)) 
 
WMT-IR 11 27% 
WMT (criterion A) 10 30% 
brain injury (in community residential 
care, moderate / severe (post-traumatic 
amnesia >24h, GCS <12/15)) 
WMT (criterion A) 19 45% 
coin-in-hand test (ns) 20 5% 
autobiographical memory index (ns) 18 78% 
digit-symbol coding (ns) 17 20% 
mental control (ns) 19 26% 
Camden memory test for faces (<5th 
age-related percentile for oldest 
normative age group) 
18 28% 
Terry et al. 2015 former high school footballers with >2 
concussions >15 years prior 
MSVT (criterion A) 25 0% 
Bodner et al. 2019 acute stroke with first manifestation of 
aphasia (mild to severe) 
TOMM 2nd trial (≤45) 15 7% 
TOMM retention trial (≤45) 0% 
Rey 15-item test pass/fail ) (<8) 60% 
RDS (<7) 73% 
Reliable spatial span (<7) 40% 
Oudman et al. 
2019 
Korsakoff amnesia TOMM 2nd trial (not stated) 20 10% 
VAT-E IR (not stated) 5% 
VAT-E DR (not stated) 5% 




bilateral hippocampal atrophy secondary 
to anoxic brain injury 
WMT (criterion A) 3 0% 
Carone et al. 2014 surgical removal of left anterior 
hippocampus and parahippocampal gyrus 








Table 7 - Degenerative brain disease (percentages ≥25% highlighted in red) 
Degenerative brain disease 
Study Clinical definition Test (cut-off) N % to fail 
test 
Teichner et al. 
2004 
dementia TOMM (<45 trial 2 or retention trial) 21 76% 
Carone et al. 
2014 
non-specific progressive dementia  MSVT (criterion A) 1 100%* 
WMT (criterion A) 100%* 
RDS (not stated: assume ≤7) 0% 
Davis 2018 dementia Digit Symbol Coding (age-adjusted 
scaled score) (<6) 
5761 16% 
Digit Span (age-adjusted scaled 
score) (<6) 
11% 
Logical memory (<14) 68% 
Semantic word generation raw 
score (<13) 
60% 
Trail Making Test B:A ratio (<1.5) 2% 





RDS pass/fail (≤6) 30% 
Three digits timed (>2s) 50 18% 
Four digits timed (>4s) 48 10% 
Vocabulary - digit span (>5) 149 3% 
Dot counting (escore <17) 80 50% 
TOMM trial 2 (≤45) 20 55% 
Warrington words (<33) 39 41% 
Rey 15-item test free recall (<9) 105 74% 
Rey 15-item test recognition 
equation (<20) 
50 86% 
Logical memory RMI (≤136) 43 23% 
Finger tapping (men ≤35, women 
≤28) 
55 31% 
b-Test (≥160) 34 53% 
Rey word recognition (men ≤5, 
women ≤7) 
32 22% 
Rey word recognition equation (≤9) 32 44% 
RAVLT equation (≤12) 64 87% 
Rey-Osterreith equation (≤47) 51 63% 
Duff et al. 2011 probable Alzheimer's Disease RBANS Effort Index (>3) 126 33% 
Fazio et al. 2019 dementia (major neurocognitive disorder)  Rey 15-Item (<20 on recall & 
recognition) 
52 90% 
RDS pass/fail (≤5) 9% 
Green et al. 
2011 
dementia (probable, mild, and moderate: 
CDR 0.5 - 2)  
WMT (criterion A) 42 71%* 
MSVT (criterion A) 23 48%* 
Howe et al. 
2007 
dementia (early) MSVT (criterion A) 13 38%* 
dementia (advanced) MSVT (criterion A) 18 83%** 
Loring et al. 
2016 
early Alzheimer’s dementia (MMSE 20-
26,+NINCDS/ARDRA criteria probable)  
RDS (≤5) 176 3% 
RDS (≤7) 34% 
AVLT recognition 70% 
Merten et al. 
2007 
mild Alzheimer’s dementia (mean MMSE 
score 22.2, SD 2.9) 
ASTM (<85) 20 90% 
WMT IR (<34) 90% 




WMT DR (<34) 90% 
WMT consistency (<34) 95% 
TOMM 2nd trial (<45) 30% 
TOMM delay trial (<45) 50% 
Meyer et al. 
2017 
mild Alzheimer’s dementia VAT-E IR (≤20) 26 0% 
VAT-E DR (≤19) 0% 
VAT-E CNS (≤19) 4% 
Rudman et al. 
2011 
mild dementia diagnosed before 65 
(CAMCOG) 
coin in hand (ns) 20 0% 
dot counting time (grouped > 
ungrouped) 
0% 
dot counting errors (ns) 10% 
Rey 15-item test (ns) 15% 
TOMM (ns) 5% 
NV-MSVT (ns) 50% 
MSVT (ns) 35% 
moderate/severe dementia diagnosed 
before 45 (CAMCOG) 
coin in hand (ns) 22 23% 
dot counting time (grouped > 
ungrouped) 
0% 
dot counting errors (ns) 32% 
Rey 15-item test 73% 
TOMM (ns) 64% 
NV-MSVT (ns) 77% 
MSVT (ns) 73% 
Sieck et al. 2013 Huntington Disease RBANS EI (>3) 121 18% 
RBANS ES (only the 43 scoring <19 
list recognition and <9 digit span) 
(<12) 
43 70% 
TOMM (<45 on trial 2) 36 8% 
Singhal et al. 
2009 
advanced dementia (6 AD, 4 
undetermined) 
MSVT (criterion A) 10 100%* 
NV-MSVT (criterion A) 100%* 
Walter et al.  moderate-severe dementia TOMM trial 2 (≤45) 28 21% 
Wodushek et 
al.  
Parkinson's disease candidates for DBS MSVT (criterion A) 47 10%*** 
MSVT (criterion A) 6% 
RDS (≤6) 5% 
vocabulary – digit span (scaled 
score) (>5) 
4% 
CVLT-II forced choice (<14) 0% 
Zenisek et al. 
2016 
Alzheimer’s dementia RDS (≤7) 133 39% 
RDS (≤6) 20% 
RDS (≤5) 8% 
Vascular dementia RDS (≤7) 8 63% 
RDS (≤6) 25% 
RDS (≤5) 0% 
Dementia with Lewy Bodies RDS (≤7) 27 37% 
RDS (≤6) 15% 
RDS (≤5) 0% 
Frontotemporal dementia RDS (≤7) 15 53% 
RDS (≤6) 27% 
RDS (≤5) 13% 
Parkinsonian syndromes RDS (≤7) 20 35% 
RDS (≤6) 20% 
RDS (≤5) 5% 




Rossetti et al. 
2018 
Parkinson's disease – deep brain 
stimulation surgical candidates  
WMT (criterion A) 20 5% 
Woods et al. 
2003 
HIV-associated neurocognitive disorders Hiscock Digit Memory Test (<90%) 82 2% 
Van der Werf et 
al. 2000 
Multiple sclerosis ASTM (<86) 40 13% 
* all who failed had a dementia / severe impairment profile (profile of results suggestive of failure due to dementia rather 
than invalid performance) 
**13/15 who failed had dementia / severe impairment profile 
*** examinees with dementia / severe impairment profile excluded 
 
  




Table 8 - Psychiatric disorders (percentages ≥25% highlighted in red) 
Psychiatric disorders 
Study Clinical definition Test (cut-off) N % to 
fail 
test 
Back et al. 1996 schizophrenia Rey 15-item test (<9) 30 
 
13% 
Rey dot-counting (mean grouped-dot counting time 
> 4.8x AND grouped time:ungrouped time ≤ 2:1 
13% 
Hiscock Forced Choice, 18-trial version (<90%) 27% 
Gorissen et al. 
2005 
schizophrenia WMT (criterion A) 64 72% 
Moore et al. 
2013 
schizophrenia or  
schizoaffective disorder 
RBANS EI (> 3) 128 23% 
Hunt et al. 2014 schizophrenia (63%) or 
schizoaffective disorder (37%)  
Validity Indicator Profile (VIP) verbal (ns) 53 60% 
VIP non-verbal (ns) 54 83% 
TOMM trial 2 28% 
TOMM retention 17% 
STMS (short test of mental status) (≤29) 35% 
reading subtest of WRAT-4 (≤79) 22% 
Stevens et al. 
2014 
schizophrenia WMT (criterion A) 70 26% 
Strauss et al. 
2015 
schizophrenia or  
schizoaffective disorder 
VSVT 97 1% 
WMT (criterion A) 46 15% 
Morra et al. 
2015 
schizophrenia (289),  
schizoaffective disorder (32) 
or another psychotic disorder 
(9) 
RBANS Effort Index (>3) 330 9% 
Whearty et al. 
2015 
schizophrenia (47) or  
schizoaffective disorder (13) 
RDS (≤6) 60 28% 
Finger tapping (≤35 male, ≤28 female) 36% 
Schroeder et al. 
2011 
psychotic psychiatric disorder sentence repetition (≤10) 104 2% 
RDS (≤ 7) 17% 
RDS (≤ 6) 4% 
CVLT-II forced choice (≤14) 8% 
rarely missed index (≤ 136) 10% 
finger tapping (≤ 35 males, ≤ 28 females) 3% 
dot counting (≥ 20) 3% 
dot counting (≥ 17) 3% 
RCTF (≤3 true positive or > 4 false positive) 4% 
Dandachi-
Fitzgerald et al. 
2011 
personality disorders ASTM  16 31% 
mood and anxiety disorders ASTM  34 24% 
Autism spectrum disorder ASTM  25 16% 
substance abuse/dependence ASTM  11 18% 
Attention deficit hyperactivity 
disorder 
ASTM (<85) 56 14% 
psychotic disorder ASTM 8 25% 
Ruocco 2016 borderline personality 
disorder 
VSVT hard items (≤ 15/24) 50 2% 
Lee et al. 2000 major depressive disorder 
(middle aged or elderly) 
Rey 15-item test ( <9 OR spatial score < 9) 64 5% 
Rey dot-counting (mean grouped counting time ≥ 
mean ungrouped dot counting time OR > 3 errors OR 
ungrouped time > 180s OR grouped time > 130s 
0% 




Rees et al. 2001 depression (psychiatric 
inpatients) 
TOMM (<45 trial 2 or retention trial) 26 0% 
Price et al. 2011 methamphetamine 
dependence 









Table 9 - Other conditions (percentages ≥25% highlighted in red) 
Other conditions 
 
Study Clinical definition Test (cut-off) N % to fail 
test 
Heintz et al. 2013 Gilles de la Tourette syndrome ASTM (<85) 13 23% 
Janssen et al. 
2013 
HIV-1 infected patients ASTM (<85) 30 17% 
Paul et al. 2017 HIV-infected individuals on stable combination 
antiretroviral therapy 
TOMM trial 1 
(<45) 
111 15% 
Rossetti et al. 
2018 
Essential tremor – deep brain stimulation surgical 
candidates  
WMT criterion A 10 20%* 
Dorociak et al. 
2018 
Sickle cell disease TOMM trial 1 (< 
40) 
54 4% 





RDS (≤ 6) 9% 
RDS (≤ 7) 33% 






Figure 1 – Selection of included studies 
 
1641 titles and abstracts 
screened 
196 full texts screened 
58 studies included in initial 
review  
1445 excluded (did not meet criteria) 
   138 studies excluded after full-text review: 
 
- 71 mixed clinical groups / performance by diagnosis not 
reported 
- 30 ≥ 50% participants known to be litigating 
- 16 no pass/fail performance validity results reported 
- 8 of active military or military veterans 
- 3 clinical groups preselected after passing validity tests 
- 2 non-repeatable validity tests 
- 2 ≥ 50% participants known to be seeking ‘workers 
compensation’ or disability benefits 
- 2 conference abstracts only 
- 1 paediatric population 
- 1 participants with ADHD 
- 1 forensic participants 
- 1 clinical patients asked to simulate impairment 
 
  
69 studies included in final 
review  
11 additional studies identified from an 














































































































Parkinson's disease Schizophrenia / psychosis
Intellectual disability MCI Mild TBI Moderate severe TBI


































Word Memory Test Test of Memory Malingering
Medical Symptom Validity Test Non−verbal Medical Symptom Validity test
Reliable digit span (<6) Reliable digit span(<7)
Reliable digit span (<8) Amsterdam Short−Term Memory Test
Victoria Symptom Validity Test Rey 15−item Test
RBANS Effort Index 'Coin in the hand' Test
Validity test failure rates in discrete clinical groups




List of included studies 
Allen MD, Wu TC, Bigler ED. Traumatic brain injury alters word memory test performance by slowing response time and 
increasing cortical activation: An fMRI study of a symptom validity test. Psychol Inj Law 2011; 4: 140–6. 
Back C, Boone KB, Edwards C, Parks C, Al E. The performance of schizophrenics on three cognitive tests of malingering, 
Rey 15-Item Memory Test, Rey Dot Counting, and Hiscock Forced-Choice Method. Assessment 1996; 3: 449–57. 
Bar-On Kalfon T, Gal G, Shorer R, Ablin JN. Cognitive functioning in fibromyalgia: The central role of effort. J Psychosom 
Res 2016; 87: 30–6. 
Bodner T, Merten T, Benke T. Performance validity measures in clinical patients with aphasia. J Clin Exp Neuropsychol 
2019; 41: 476–83. 
Carone DA, Ben-Porath YS. Dementia does not preclude very reliable responding on the MMPI-2 RF: a case report. Clin 
Neuropsychol 2014; 28: 1019–29. 
Carone DA, Green P, Drane DL. Word memory test profiles in two cases with surgical removal of the left anterior 
hippocampus and parahippocampal gyrus. Appl Neuropsychol Adult 2014; 21: 155–60. 
Cragar DE, Berry DTR, Fakhoury TA, Cibula JE, Schmitt FA. Performance of Patients with Epilepsy or Psychogenic Non-
Epileptic Seizures on Four Measures of Effort. Clin Neuropsychol 2006; 20: 552–66. 
Dandachi-FitzGerald B, Ponds RWHM, Peters MJ V, Merckelbach H. Cognitive underperformance and symptom over-
reporting in a mixed psychiatric sample. Clin Neuropsychol 2011; 25: 812–28. 
Davis JJ. Performance validity in older adults: Observed versus predicted false positive rates in relation to number of 
tests administered. J Clin Exp Neuropsychol 2018; 40: 1013–21. 
Dean A, Victor T, Boone K, Philpott L, Hess A. Dementia and effort test performance. Clin Neuropsychol 2009; 23: 133–
52. 
Dorociak K, Schulze E, Piper L, Molokie R, JK J. Performance validity testing in a clinical sample of adults with sickle cell 
disease. Clin Neuropsychol 2018; 32: 81–97. 
Drane DL, Williamson DJ, Stroup ES, et al. Cognitive impairment is not equal in patients with epileptic and psychogenic 
nonepileptic seizures. Epilepsia 2006; 47: 1879–86. 
Duff K, Spering CC, O’Bryant SE, et al. The RBANS effort index: Base rates in geriatric samples. Appl Neuropsychol 2011; 
18: 11–7. 
Erdodi LA, Abeare CA, Lichtenstein JD, et al. Wechsler Adult Intelligence Scale-Fourth Edition (WAIS-IV) processing speed 
scores as measures of noncredible responding: The third generation of embedded performance validity indicators. 
Psychol Assess 2017; 29: 148–57. 
Erdodi L, Roth R. Low scores on BDAE Complex Ideational Material are associated with invalid performance in adults 
without aphasia. Appl Neuropsychol Adult 2017; 24: 264–74. 
Fazio RL, Faris AN, Yamout KZ. Use of the Rey 15-Item Test as a performance validity test in an elderly population. Appl 
Neuropsychol Adult 2019; 26: 28–35. 
Goldberg J, Miller H. Performance of psychiatric inpatients and intellectually deficient individuals on a task that assesses 
the validity of memory complaints. J Clin Psychol 1986; 42: 792–5. 
Goodrich-Hunsaker NJ, Hopkins RO. Word memory test performance in amnesic patients with hippocampal damage. 
Neuropsychology 2009; 23: 529–34. 
Gorissen M, Sanz JC, Schmand B. Effort and cognition in schizophrenia patients. Schizophr Res 2005; 78: 199–208. 
Green P, Flaro L. Results From Three Performance Validity Tests (PVTs) in Adults With Intellectual Deficits. Appl 
Neuropsychol Adult 2015; 22: 293–303. 




Green P, Montijo J, Brockhaus R. High specificity of the Word Memory Test and Medical Symptom Validity Test in groups 
with severe verbal memory impairment. Appl Neuropsychol 2011; 18: 86–94. 
Grote CL, Kooker EK, Garron DC, Nyenhuis DL, Smith CA, Mattingly ML. Performance of compensation seeking and non-
compensation seeking samples on the Victoria symptom validity test: cross-validation and extension of a 
standardization study. J Clin Exp Neuropsychol 2000; 22: 709–19. 
Hampson NE, Kemp S, Coughlan AK, Moulin CJA, Bhakta BB. Effort test performance in clinical acute brain injury, 
community brain injury, and epilepsy populations. Appl Neuropsychol Adult 2014; 21: 183–94. 
Heintz CEJ, van Tricht MJ, van der Salm SMA, et al. Neuropsychological profile of psychogenic jerky movement disorders: 
importance of evaluating non-credible cognitive performance and psychopathology. J Neurol Neurosurg Psychiatry 
2013; 84: 862–7. 
Hill S, Ryan L, Kennedy C, Malamut B. The relationship between measures of declarative memory and the test of 
memory malingering in patients with and without temporal lobe dysfunction. J Forensic Neuropsychol 2003; 3: 1–18. 
 Hoskins LL, Binder LM, Chaytor NS, Williamson DJ, Drane DL. Comparison of oral and computerized versions of the word 
memory test. Arch Clin Neuropsychol 2010; 25: 591–600. 
Howe LLS, Anderson AM, Kaufman DAS, Sachs BC, Loring DW. Characterization of the Medical Symptom Validity Test in 
evaluation of clinically referred memory disorders clinic patients. Arch Clin Neuropsychol 2007; 22: 753–61. 
Hunt S, Root JC, Bascetta BL. Effort testing in schizophrenia and schizoaffective disorder: validity indicator profile and 
test of memory malingering performance characteristics. Arch Clin Neuropsychol 2014; 29: 164–72. 
Iverson GL, Le Page J, Koehler BE, Shojania K, Badii M. Test of Memory Malingering (TOMM) scores are not affected by 
chronic pain or depression in patients with fibromyalgia. Clin Neuropsychol 2007; 21: 532–46. 
Janssen MAM, Bertens D, Kessels L, Kessels RPC, Koopmans PP. A case-control pilot study on cognitive functioning, 
symptom validity and psychological wellbeing in HIV-1-infected patients in the Netherlands. Int J STD AIDS 2013; 24: 
387–91. 
Kanser RJ, Rapport LJ, Bashem JR, Hanks RA. Detecting malingering in traumatic brain injury: Combining response time 
with performance validity test accuracy. Clin Neuropsychol 2019; 33: 90–107. 
Keary T, Frazier T, Belzile C, et al. Working memory and intelligence are associated with victoria symptom validity test 
hard item performance in patients with intractable epilepsy. J Int Neuropsychol Soc 2013; 19: 314–23. 
Kemp S, Coughlan AK, Rowbottom C, Wilkinson K, Teggart V, Baker G. The base rate of effort test failure in patients with 
medically unexplained symptoms. J Psychosom Res 2008; 65: 319–25. 
Lee A, Boone K, Lesser I, Wohl M, Wilkins S, Parks C. Performance of older depressed patients on two cognitive 
malingering tests: False positive rates for the Rey 15-item memorization and Dot Counting Tests. Clin Neuropsychol 
2000; 14: 303–8. 
Loring D, Lee G, Meador K. Victoria Symptom Validity Test performance in non-litigating epilepsy surgery candidates. J 
Clin Exp Neuropsychol 2005; 27: 610–7. 
Loring DW, Goldstein FC, Chen C, et al. False-Positive Error Rates for Reliable Digit Span and Auditory Verbal Learning 
Test Performance Validity Measures in Amnestic Mild Cognitive Impairment and Early Alzheimer Disease. Arch Clin 
Neuropsychol 2016; 31: 313–31. 
Macciocchi SN, Seel RT, Alderson A, Godsall R. Victoria Symptom Validity Test performance in acute severe traumatic 
brain injury: implications for test interpretation. Arch Clin Neuropsychol 2006; 21: 395–404. 
Macciocchi SN, Seel RT, Yi A, Small S. Medical Symptom Validity Test Performance Following Moderate-Severe 
Traumatic Brain Injury: Expectations Based on Orientation Log Classification. Arch Clin Neuropsychol 2017; 32: 339–48. 
Maiman M, Del Bene VA, MacAllister WS, et al. Reliable digit span: Does it adequately measure suboptimal effort in an 
adult epilepsy population? Arch Clin Neuropsychol 2019; 34: 259–67. 
Merten T, Bossink L, Schmand B. On the limits of effort testing: symptom validity tests and severity of neurocognitive 
symptoms in nonlitigant patients. J Clin Exp Neuropsychol 2007; 29: 308–18. 




Meyer SRA, de Jonghe JFM, Schmand B, Ponds RWHM. The Visual Association Test-Extended: a cross-sectional study of 
the performance validity measures. Clin Neuropsychol 2017; 31: 798–813. 
Moore R, Davine T, Harmell A, Cardenas V, Palmer B, Mausbach B. Using the repeatable battery for the assessment of 
neuropsychological status (RBANS) effort index to predict treatment group attendance in patients with schizophrenia. J 
Int Neuropsychol Soc 2013; 19: 198–205. 
Morra L, Gold J, Sullivan S, Strauss G P. Predictors of neuropsychological effort test performance in schizophrenia. 
Schizophr Res 2015; 162: 205–10. 
Novitski J, Steele S, Karantzoulis S, Randolph C. The Repeatable Battery for the Assessment of Neuropsychological Status 
Effort scale. Arch Clin Neuropsychol 2012; 27: 190–5. 
Oudman E, Krooshof E, van Oort R, Lloyd B, Wijnia JW, Postma A. Effects of korsakoff amnesia on performance and 
symptom validity testing. Appl Neuropsychol Adult 2019;: 1-9 https://doi.org/10.1080/23279095.2019.1576180 
Paul R, Rhee G, Baker LM, Vaida F, Cooley SA, Ances BM. Effort and neuropsychological performance in HIV-infected 
individuals on stable combination antiretroviral therapy. J Neurovirol 2017; 23: 725–33. 
Price K, Desantis S, Simpson A, et al. The impact of clinical and demographic variables on cognitive performance in 
methamphetamine-dependent individuals in rural South Carolina. Am J Addict 2011; 20: 447–55. 
Rees L, Tombaugh T, Gansler D, Moczynski N. Five validation experiments of the Test of Memory Malingering (TOMM). 
Psychol Assess 1998; 10: 10–20. 
Rees L, Tombaugh T, Boulay L. Depression and the Test of Memory Malingering. Arch Clin Neuropsychol 2001; 16: 501–
6. 
Roor JJ, Knoop H, Dandachi-FitzGerald B, Peters MJ V, Bleijenberg G, Ponds RWHM. Feedback on underperformance in 
patients with chronic fatigue syndrome: The impact on subsequent neuropsychological test performance. Appl 
Neuropsychol Adult 2018;27(2): 188-196 
Rossetti MA, Collins RL, York MK. Performance Validity in Deep Brain Stimulation Candidates. Arch Clin Neuropsychol 
2018; 33: 508–14. 
Rudman N, Oyebode JR, Jones CA, Bentham P. An investigation into the validity of effort tests in a working age dementia 
population. Aging Ment Health 2011; 15: 47–57. 
Ruocco A. Compliance on neuropsychological performance validity testing in patients with borderline personality 
disorder. Psychol Assess 2016; 28: 345–50. 
Schroeder RW, Marshall PS. Evaluation of the appropriateness of multiple symptom validity indices in psychotic and 
non-psychotic psychiatric populations. Clin Neuropsychol 2011; 25: 437–53. 
Sherer M, Davis LC, Sander AM, et al. Factors Associated with Word Memory Test Performance in Persons with 
Medically Documented Traumatic Brain Injury. Clin Neuropsychol 2015; 29: 522–41. 
Sieck BC, Smith MM, Duff K, Paulsen JS, Beglinger LJ. Symptom validity test performance in the Huntington Disease 
Clinic. Arch Clin Neuropsychol 2013; 28: 135–43. 
Singhal A, Green P, Shankar K, Gill D. High specificity of the Medical Symptom Validity Test in patients with very severe 
memory impairment. Arch Clin Neuropsychol 2009; 24: 721–8. 
Stevens A, Schneider K, Liske B, Hermle L, Huber H, Hetzel G. Is subnormal cognitive performance in schizophrenia due 
to lack of effort or to cognitive impairment? Ger J Psychiatry 2014; 17: 1–9. 
Strauss G, Morra L, Sullivan S, Gold J. The role of low cognitive effort and negative symptoms in neuropsychological 
impairment in schizophrenia. Neuropsychology 2015; 29: 282–91. 
Teichner G, Wagner M. The Test of Memory Malingering (TOMM): Normative data from cognitively intact, cognitively 
impaired, and elderly patients with dementia. Arch Clin Neuropsychol 2004; 19: 455–64. 
Terry DP, Adams TE, Ferrara MS, Miller LS. fMRI hypoactivation during verbal learning and memory in former high 
school football players with multiple concussions. Arch Clin Neuropsychol 2015; 30: 341–55. 




Tyson B, Baker S, Greenacre M, et al. Differentiating epilepsy from psychogenic nonepileptic seizures using 
neuropsychological test data. Epilepsy Behav 2018; 87: 39–45. 
Van Der Werf S, Prins J, Jongen P, Van Der Meer J, Bleijenberg G. Abnormal neuropsychological findings are not 
necessarily a sign of cerebral impairment. A matched comparison between chronic fatigue syndrome and multiple 
sclerosis. Neuropsychiatry, Neuropsychol Behav Neurol 2000; 13: 199–203. 
Walter J, Morris J, Swier-Vosnos A, Pliskin N. Effects of severity of dementia on a symptom validity measure. Clin 
Neuropsychol 2014; 28: 1197–208. 
Whearty K, Allen C, Lee B, GP S. The evaluation of insufficient cognitive effort in schizophrenia in light of low IQ scores. J 
Psychiatr Res 2015; 68: 397–404. 
Wodushek TR, Domen CH. Comparing two models of performance validity assessment in patients with parkinson’s 
disease who are candidates for deep brain stimulation surgery. Appl Neuropsychol Adult 2018; 27(1): 9-21 
Woods SP, Conover E, Weinborn M, et al. Base rate of Hiscock Digit Memory Test failure in HIV-associated 
neurocognitive disorders. Clin Neuropsychol 2003; 17: 383–9. 
Wu TC, Allen MD, Goodrich-Hunsaker NJ, Hopkins RO, Bigler ED. Functional neuroimaging of symptom validity testing in 
traumatic brain injury. Psychol Inj Law 2010; 3: 50–62. 
Zenisek R, Millis SR, Banks SJ, Miller JB. Prevalence of below-criterion Reliable Digit Span scores in a clinical sample of 
older adults. Arch Clin Neuropsychol 2016; 31: 426–33. 
 
